TP53 and cancer: These observations are in accordance with the work of Donehower et al. 5, demonstrating that more than 90% of TP53-mutant cancers exhibit second allele loss of expression, either by mutation, chromosomal deletion, or copy-neutral loss of heterozygosity, leading to alteration of the p53 protein level in most cases.